PanTHERA CryoSolutions is pleased to announce that it is receiving advisory services and up to $395,700 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support PanTHERA CryoSolutions’ research and development project.
PanTHERA CryoSolutions has been working on developing its patented ice recrystallization inhibitors (IRIs) which increases overall post-thaw cell recovery and quality by reducing damage during the cryopreservation process. This funding will accelerate the research, development, and commercialization of these IRIs.
“We are very grateful for the generous support from the Government of Canada through NRC IRAP. This funding will help accelerate our efforts to bring this made-in-Canada technology to the global cell and gene therapy markets.” says Dr. Jason Acker, CEO, PanTHERA CryoSolutions.
About PanTHERA CryoSolutions
PanTHERA CryoSolutions is a Canadian corporation that designs and manufactures cryopreservation solutions for cells, tissues and organs. Our patented ice recrystallization inhibitor (IRI) technology enhances currently available alternatives and increasing post-thaw cell recovery and function and providing superior cryopreservation for our customers.
